Table 1.

Baseline characteristics of the patients included in the study.

Characteristic		Apixaban 5 mg (n = 53)
Median age (years)		70 (65;77)
Male n (%)		32 (60.4%)
BMI (kg/m2)		28 (24.6;31.3)
S (m2)		1.9 (1.6;2.1)
AF type n (%)	paroxysmal	11 (20.8%)
	persistent	12 (22.6%)
	permanent	30 (56.6%)
Prior VKA n (%)		21 (39.6%)
CHA2DS2-VASC score	1–2	10 (18.8%)
	≥3	43 (81.2%)
CrCl mL/min/1.72 m2		77.5 (64.2;90.0)
Minor bleeding n (%)		6 (11.3%)
Plasma concentrations (ng/mL)	trough	132.3 (90.4;184.2)
	peak	287.3 (198.6;396.8)

AF—atrial fibrillation; CrCl—creatinine clearance; BMI—body mass index, S—body surface; VKA—vitamin-K antagonists.